The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension

BACKGROUND AND AIMS: Angiogenesis is critically involved in the development of liver fibrosis, portal hypertension (PHT) and hepatocellular carcinoma (HCC). Regorafenib is a novel second-line therapy for HCC, but might also be beneficial in fibrosis and PHT even in absence of HCC. This study investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Uschner, Frank Erhard, Schueller, Florian, Nikolova, Ivelina, Klein, Sabine, Schierwagen, Robert, Magdaleno, Fernando, Gröschl, Stefanie, Loosen, Sven, Ritz, Thomas, Roderburg, Christoph, Vucur, Michael, Kristiansen, Glen, Lammers, Twan, Luedde, Tom, Trebicka, Jonel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281422/
https://www.ncbi.nlm.nih.gov/pubmed/30546838
http://dx.doi.org/10.18632/oncotarget.26333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281422/
https://www.ncbi.nlm.nih.gov/pubmed/30546838
http://dx.doi.org/10.18632/oncotarget.26333

Ejemplares similares